Pharma's Premier Quantitative Company and Drug Evaluation Tool Designed Specifically for Business Development Available Now with a New User-Friendly Interface
Productview Plus from Decision Resources Includes Data for Over 1000 Drugs Across 147 Product Classes
WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the growth in drug sales of the top 10 pharmaceutical companies slowed to its lowest level in years in 2008 -- growing just 3.7 percent compared to 7.9 percent the year before. The performance of the top 10 companies in the U.S. market, the world's largest, was particularly poor, with sales down 3.5 percent year-over-year.
"This trend is expected to continue in the U.S. with growth in the top 10 companies forecasted to remain flat out to 2015 despite the contribution of recently seen large-scale acquisitions by Pfizer, Roche and Merck & Co.," said Stephan Gauldie Ph.D., Director at Decision Resources. "Of the top 10 pharma companies, only Roche is expected to post a compound annual growth rate above the 3 percent that is forecasted for the overall U.S. market out to 2015."
These data come from the newly updated Productview Plus, the pharmaceutical industry's premier quantitative company and drug evaluation tool designed specifically for business development. The new Productview Plus allows business planners and new product commercialization managers to quickly assess forecasts and evaluate market scenarios that will determine a company's/drug's success or failure.
"By manipulating the data by brand, therapeutic area, drug class and company, users can track market sizes, assess barriers to market entry, quickly benchmark internal forecasts or analyze the potential of licensing candidates," continued Dr. Gauldie.
Based on compa
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved